GPP
KURA icon

Great Point Partners’s Kura Oncology KURA Stock Holding History

Great Point Partners’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500,000
Closed -$10.4M – 38
2021
Q2 		$10.4M Buy
+500,000
New +$12.4M 2.19% 22
2020
Q2 		– Sell
-179,700
Closed -$1.79M – 39
2020
Q1 		$1.79M Sell
179,700
-674,077
-79% -$7.72M 0.19% 34
2019
Q4 		$11.7M Sell
853,777
-2,232,276
-72% -$33.1M 1.02% 23
2019
Q3 		$46.8M Buy
3,086,053
+38,253
+1% +$681K 4.3% 9
2019
Q2 		$60M Buy
3,047,800
+402,700
+15% +$6.68M 6.66% 5
2019
Q1 		$43.9M Sell
2,645,100
-124,427
-4% -$1.92M 4.34% 13
2018
Q4 		$38.9M Buy
2,769,527
+650,421
+31% +$8.62M 4.91% 7
2018
Q3 		$37.1M Sell
2,119,106
-508,004
-19% -$9.74M 5.78% 6
2018
Q2 		$47.8M Buy
2,627,110
+246,264
+10% +$4.17M 6.63% 2
2018
Q1 		$44.6M Buy
2,380,846
+183,563
+8% +$3.57M 6.63% 3
2017
Q4 		$33.6M Buy
2,197,283
+446,396
+25% +$6.58M 5.74% 3
2017
Q3 		$26.2M Buy
+1,750,887
New +$16.4M 5.09% 8

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Great Point Partners's KURA Position: Q3 2021 in Review

Great Point Partners sold out of Kura Oncology (KURA) in Q3 2021, closing a stake of 500,000 shares — an estimated $10.4M sold.

Great Point Partners first reported a position in KURA in Q3 2017 and held it in 12 quarters. The position peaked at $60M in Q2 2019. 152 funds tracked by Wall St. Rank hold KURA as of Q3 2021.

  • Great Point Partners reported no remaining Kura Oncology position as of Q3 2021 after selling out during the quarter.
  • Great Point Partners sold 500,000 Kura Oncology shares in Q3 2021, an estimated $10.4M.
  • Great Point Partners first reported a position in Kura Oncology in Q3 2017 and held it in 12 quarters.
  • Great Point Partners's Kura Oncology position peaked at $60M in Q2 2019.
  • 152 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2021.

Based on Great Point Partners's 13F filing for Q3 2021, filed 15 Nov 2021.